



- (51) **International Patent Classification:**
A61K 8/97 (2006.01) *A61K 36/28* (2006.01)
- (21) **International Application Number:**
PCT/US2013/040972
- (22) **International Filing Date:**
14 May 2013 (14.05.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/646,711 14 May 2012 (14.05.2012) US
- (71) **Applicant:** **BIOCOGENT, LLC** [US/US]; 25 Health Sciences Drive, Stony Brook, NY 11790 (US).
- (72) **Inventors:** **CECCOLI, Joseph, D.**; 26 Neil Drive, Farmingville, NY 11738 (US). **COSTELLO, Brian**; 149 Captains Way, Port Jefferson Station, NY 11776 (US).
- (74) **Agent:** **BRAGINSKY, Philip, Y.**; Tarter Krinsky & Drogin LLP, 1350 Broadway, 12th Floor, New York, NY 10018 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))

Date of publication of the amended claims: 23 January 2014

(54) **Title:** PREVENTION OF FIBROBLAST COLLAPSE

(57) **Abstract:** The present technology is directed to extracts of plants of genus *Osmanthus*, skin care compositions comprising extracts of plants of the genus *Osmanthus*; as well as to methods of formulating skin care compositions, and methods of reducing or preventing fibroblast collapse, reducing or preventing glycation, maintaining or increasing skin elasticity and firmness and reducing the appearance of aging comprising applying the skin care compositions of the present technology to the skin of a patient.



AMENDED CLAIMS

received by the International Bureau on 02 December 2013 (02.12.2013)

1. A skin care composition comprising an extract of a plant of genus *Osmanthus*.
2. (Amended) The skin care composition of claim 1, wherein the plant is chosen from *Osmanthus americanus*, *Osmanthus amatus*, *Osmanthus asiaticus* (sweet olive), *Osmanthus auratiacus*, *Osmanthus decorus*, *Osmanthus delavayi*, *Osmanthus fragrans*, *Osmanthus heterophyllus*, *Osmanthus semulatus*, *Osmanthus suavis*, *Osmanthus yunnanensis*, *Osmanthus* × *burkwoodii* (*O. delavayi* × *O. decorus*) and *Osmanthus* × *fortunei* (*O. fragrans* × *O. heterophyllus*).
3. The skin care composition of claim 1, wherein the extract is in the form of a powder or pulverized material, granule, tablet, a cream, grounds, an emulsion, a suspension or paste.
4. The skin care composition of claim 1, wherein the skin care composition is in the form of a lotion, a cream, a paste, a suspension, a gel, a liquid, an aerosol, a powder, a foam, a serum, an ointment or mixture of any of the foregoing.
5. The skin care composition of claim 1, further comprising at least one additional skin care ingredient chosen from an emollient, a surfactant, a solvent, a vitamin, a lipid, a sunscreen agent, a polymer, a moisturizer, a colorant, a maskant, a fragrance, a preservative or an exfoliating agent.

6. The skin care composition of claim 1, wherein the extract is present in an amount of about 0.001 to about 15% by weight of the skin care composition.
7. A skin care composition comprising:
- (a) about 0.001 to about 50% of an extract of a plant of genus *Osmanthus*;
 - (b) about 0.1 to about 20% of an emulsifier;
 - (c) about 0.1 to about 60% of an emollient;
 - (d) about 0.01 to about 10% of a thickener; and
 - (e) about 0.1 to about 99% water.
8. The skin care composition of claim 7, further comprising at least one additional skin care ingredient.
9. The skin care composition of claim 8, wherein the skin care ingredient is chosen from an emollient, a surfactant, a solvent, a vitamin, a lipid, a sunscreen agent, a polymer, a moisturizer, a colorant, a maskant, a fragrance, a preservative or an exfoliating agent.
10. A method of formulating a skin care composition, the method comprising the steps of:
- (a) preparing an extract of a plant of genus *Osmanthus* by preparing a combination of about 2 to about 10 parts by weight of any portion of the plant with about 90 to about 98 parts by weight of solvent; and
 - (b) combining the extract with a skin care ingredient to produce the skin care composition.

11. The method of claim 10, wherein between steps (a) and (b) the extract is turned into a powder or pulverized material, granule, tablet, a cream, grounds, an emulsion, a suspension or paste.

12. A method of applying a skin care composition according to claim 1 to the skin of a patient.

13. A method of reducing or preventing fibroblast collapse in the skin of a patient, the method comprising the step of contacting the skin care composition of claim 1 with the skin of a patient.

14. The method of claim 13, wherein the fibroblast collapse is reduced or prevented by an amount of at least about 5% when compared with the amount of fibroblast collapse on the skin of a patient that has not been contacted with the skin care composition.

15. A method of reducing the appearance of aging on the skin of a patient, the method comprising the step of contacting the skin care composition of claim 1 with the skin of a patient;

wherein the appearance of aging on the skin of the patient is reduced by at least about 5% when compared with the appearance of aging on the skin on the patient that has not been contacted with the skin care composition.

16. A method of preventing glycation of a protein in the skin of a patient, the method comprising the step of contacting the skin care composition of claim 1 with the skin of a patient;

wherein glycation of the protein is prevented by at least about 5% when compared with the glycation of a the protein in the skin of a patient that has not been contacted with the skin care composition.

17. A method of maintaining or increasing elasticity in the skin of a patient, the method comprising the step of contacting the skin care composition of claim 1 with the patient; wherein the elasticity of the skin of the patient is maintained or increased by at least about 5% when compared with the elasticity of the skin of a patient that has not been contacted with the skin care composition.

18. A method of maintaining or increasing firmness of the skin of a patient, the method comprising the step of contacting the skin care composition of claim 1 with the patient; wherein the firmness of the skin of the patient is maintained or increased by at least about 5% when compared with the firmness of the skin of a patient that has not been contacted with the skin care composition.